Bloqueo TAP guiado visualmente en la reparación laparoscópica de hernia TAPP (VIS-TAP-TAPP)
Eficacia del Bloqueo del Plano Transverso del Abdomen (TAP) Guiado Visualmente en la Recuperación Tras la Reparación Laparoscópica de Hernia Inguinal (TAPP - Preperitoneal Transabdominal)
This prospective, randomized, placebo-controlled clinical study evaluates the effectiveness of a bilateral transversus abdominis plane (TAP) block performed under direct laparoscopic guidance in reducing postoperative pain and improving recovery after laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique.
Adult patients undergoing elective laparoscopic TAPP hernia repair at the University Clinical Hospital in Olsztyn, Poland, are randomly assigned to two groups. In the experimental group, a bilateral TAP block is performed after establishing pneumoperitoneum, using 20 mL of 0.25% bupivacaine on each side (40 mL total; 100 mg total). In the control group, 20 mL of 0.9% sodium chloride is injected on each side (40 mL total) as a placebo, using the same technique and anatomical sites.
Participants, the operating surgeon, and the postoperative outcome assessor are blinded to treatment allocation. An unblinded investigator performs randomization and informs the operating room nurse which solution to prepare. The nurse provides the surgeon with an unlabeled, visually identical syringe without disclosing its contents. The unblinded investigator does not assess postoperative outcomes or collect postoperative data. The outcome assessor is not present during randomization or injection and remains unaware of allocation during postoperative assessments.
Both groups receive the same standardized general anesthesia protocol and postoperative analgesic regimen. Postoperative assessments include pain intensity measured using the Visual Analogue Scale (VAS), analgesic consumption, the need for rescue opioid analgesia, time to first analgesic request, time to mobilization, readiness for discharge assessed using the Post-Anesthetic Discharge Scoring System (PADSS), and adverse events.
The study compares postoperative pain and recovery outcomes between patients receiving laparoscopically guided TAP block with bupivacaine and those receiving placebo saline injections.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Postoperative pain remains an important factor limiting early mobilization and recovery after laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique. Multimodal analgesia combines systemic analgesics with additional approaches, including regional anesthesia. A transversus abdominis plane (TAP) block targets nerves supplying the abdominal wall and can be performed under direct laparoscopic guidance during surgery.
This single-center, prospective, randomized, placebo-controlled study evaluates the effect of a laparoscopically guided bilateral TAP block on postoperative pain and recovery after elective TAPP inguinal hernia repair at the University Clinical Hospital in Olsztyn, Poland.
The planned sample size is 116 adult participants, allocated in a 1:1 ratio to two groups of 58 participants each:
Experimental group: After pneumoperitoneum is established and the laparoscope is introduced, a bilateral TAP block is performed under direct laparoscopic guidance before mesh placement. Bupivacaine 0.25% is injected at a volume of 20 mL per side, corresponding to 50 mg per side and 100 mg in total. The injection site is approximately 2 cm below the costal margin in the anterior axillary line. Correct needle placement is confirmed visually by the characteristic elevation of the transversus abdominis muscle layer, known as the "Doyle's bulge sign."
Placebo control group: Participants undergo the same TAPP repair and receive bilateral injections of 0.9% sodium chloride, 20 mL per side (40 mL total), using the same injection technique and anatomical sites as in the experimental group.
Participants, the operating surgeon, and the postoperative outcome assessor are blinded to treatment allocation. An unblinded investigator performs randomization and informs the operating room nurse which solution to prepare. The nurse provides the surgeon with an unlabeled, visually identical syringe without disclosing its contents. The unblinded investigator does not assess postoperative outcomes or collect postoperative data. The outcome assessor is not present during randomization or injection and remains unaware of allocation during postoperative assessments.
Both groups receive the same standardized general anesthesia protocol and postoperative analgesic regimen. Analgesic administration and the timing of rescue medication are recorded.
Postoperative pain intensity is assessed using the Visual Analogue Scale (VAS; 0-10) at 0, 2, and 6 hours after the end of surgery. Site-specific assessments include the umbilical port site, the working trocar site on the operated side, the working trocar site on the opposite side, the operated groin, and the ipsilateral testicle, where applicable. Additional assessments include time to first mobilization, analgesic consumption, rescue analgesic use, and readiness for discharge using the Post-Anesthetic Discharge Scoring System (PADSS) at 6 hours. Adverse events, including hematoma, swelling, subcutaneous emphysema, and transient lower limb weakness, are recorded during the 6-hour postoperative observation period.
Exclusion criteria include chronic analgesic use, chronic pain syndromes, psychiatric disorders, alcohol or opioid dependence, recurrent hernias, and emergency surgery. All participants provide written informed consent before enrollment.
The primary outcome is postoperative pain intensity at rest measured using the VAS at 2 hours after the end of surgery. Secondary outcomes include pain intensity at 0 and 6 hours, site-specific pain intensity, analgesic consumption during the first 6 hours, the proportion of participants requiring rescue opioid analgesia, time to first analgesic request, time to mobilization, readiness for discharge assessed using PADSS at 6 hours, and adverse events.
Statistical analyses compare postoperative pain, analgesic requirements, and recovery outcomes between the bupivacaine and placebo groups. The study hypothesis is that a laparoscopically guided bilateral TAP block with bupivacaine reduces postoperative pain and improves early recovery compared with placebo saline injections.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Warmisko-mazurskie
-
Olsztyn, Warmisko-mazurskie, Polonia, 10-041
- University Clinical Hospital in Olsztyn, Department of General and Oncological Surgery
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 18-80 years
- Elective laparoscopic inguinal hernia repair using the TAPP (Transabdominal Preperitoneal) technique
- ASA physical status I-III
- Ability to provide written informed consent
- No contraindications to regional anesthesia or local anesthetic administration
Exclusion Criteria:
- Recurrent or strangulated inguinal hernia
- Emergency surgery
- Chronic pain syndromes or preoperative opioid use
- Known allergy or hypersensitivity to local anesthetics (bupivacaine or similar)
- Severe hepatic or renal impairment
- Psychiatric disorders or inability to provide informed consent
- Conversion to open surgery during the procedure
- Technical difficulties preventing TAP block administration
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: TAP Block Group (Laparoscopic TAP Block with Bupivacaine)
After pneumoperitoneum is established and the laparoscope is introduced, a bilateral Transversus Abdominis Plane (TAP) block is performed under direct laparoscopic vision. Using a needle and syringe, 20 ml of 0.25% bupivacaine is injected on each side, approximately 2 cm below the costal margin in the anterior axillary line. The correct placement of the local anesthetic is confirmed by the visible "Doyle's bulge sign." Patients receive standard general anesthesia and postoperative pain management identical to the control group. |
A bilateral transversus abdominis plane (TAP) block is performed under direct laparoscopic guidance after pneumoperitoneum is established and before mesh placement during TAPP inguinal hernia repair. Using a needle and syringe, 20 mL of 0.25% bupivacaine is injected on each side (40 mL total; 100 mg total), approximately 2 cm below the costal margin in the anterior axillary line. Correct needle placement is confirmed visually by the characteristic "Doyle's bulge sign." This technique allows direct laparoscopic visualization of the injection site.
Otros nombres:
|
|
Comparador de placebos: Control Group (Placebo Saline Injection)
Participants undergo standard laparoscopic inguinal hernia repair using the transabdominal preperitoneal (TAPP) technique. Instead of bupivacaine, 20 mL of 0.9% sodium chloride is injected on each side (40 mL total) as a placebo, using the same visually guided injection technique and anatomical sites as in the experimental group. All patients receive the same standardized general anesthesia protocol and postoperative analgesic regimen as those in the experimental group. |
Bilateral injection of 0.9% sodium chloride, 20 mL per side (40 mL total), into the transversus abdominis plane under laparoscopic visual guidance. The placebo is administered at the same anatomical sites and using the same technique as bupivacaine in the experimental group. An operating room nurse prepares a visually identical syringe without disclosing its contents to the operating surgeon. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Postoperative pain intensity at rest (VAS score) at 2 hours after TAPP hernia repair
Periodo de tiempo: 2 hours after the end of surgery
|
Postoperative pain intensity at rest is assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable), at 2 hours after the end of surgery. Assessment is performed by an outcome assessor blinded to treatment allocation. Scores are compared between the bupivacaine TAP block group and the placebo saline injection group. |
2 hours after the end of surgery
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Postoperative pain intensity at rest (VAS score) at 0 and 6 hours after surgery
Periodo de tiempo: 0 and 6 hours after the end of surgery
|
Postoperative pain intensity at rest is assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst pain imaginable), immediately after surgery (0 hours) and at 6 hours after the end of surgery. Assessment is performed by an outcome assessor blinded to treatment allocation. |
0 and 6 hours after the end of surgery
|
|
Time to first mobilization
Periodo de tiempo: Within 6 hours after the end of surgery
|
The time (in hours) from the end of surgery to the patient's first ambulation will be recorded. |
Within 6 hours after the end of surgery
|
|
Postoperative recovery score (PADSS)
Periodo de tiempo: 6 hours after surgery
|
Recovery will be assessed using the Post Anesthesia Discharge Scoring System (PADSS), 0-10; higher scores indicate greater readiness for discharge. A score ≥9 will indicate readiness for discharge. |
6 hours after surgery
|
|
Incidence of postoperative complications
Periodo de tiempo: Within 6 hours after the end of surgery
|
Early postoperative complications such as hematoma, swelling, subcutaneous emphysema, or transient lower limb weakness will be recorded. |
Within 6 hours after the end of surgery
|
|
Participants requiring rescue opioid analgesia
Periodo de tiempo: First 6 hours after the end of surgery
|
Proportion of participants receiving rescue oxycodone during the first 6 postoperative hours. |
First 6 hours after the end of surgery
|
|
Total oxycodone consumption
Periodo de tiempo: First 6 hours after the end of surgery
|
Total dose of oxycodone administered to each participant, expressed in milligrams. |
First 6 hours after the end of surgery
|
|
Total metamizole consumption
Periodo de tiempo: First 6 hours after the end of surgery
|
Total dose of metamizole administered to each participant, expressed in grams. |
First 6 hours after the end of surgery
|
|
Total paracetamol consumption
Periodo de tiempo: First 6 hours after the end of surgery
|
Total dose of paracetamol administered to each participant, expressed in grams. |
First 6 hours after the end of surgery
|
|
Time to first analgesic request
Periodo de tiempo: First 6 hours after the end of surgery
|
Time in hours from the end of surgery to the participant's first request for analgesic medication. |
First 6 hours after the end of surgery
|
|
Site-specific postoperative pain intensity
Periodo de tiempo: 0, 2, and 6 hours after the end of surgery
|
Pain intensity is assessed using the VAS (0-10; higher scores indicate worse pain) separately at the umbilical port site, ipsilateral and contralateral working trocar sites, operated groin, and ipsilateral testicle, where applicable. |
0, 2, and 6 hours after the end of surgery
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Marek Kowalczyk, PhD, MD, Clinic of Oncological and General Surgery, University Clinical Hospital in Olsztyn, Olsztyn, Poland
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Actual)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Dolor
- Manifestaciones neurológicas
- Complicaciones Postoperatorias
- Procesos Patológicos
- Condiciones Patológicas, Anatómicas
- Hernia
- Hernia Abdominal
- Condiciones Patológicas, Signos y Síntomas
- Signos y síntomas
- Dolor Postoperatorio
- Hernia Inguinal
- Químicos orgánicos
- Aniluros
- Amidas
- Compuestos anilina
- Amina
- Químicos inorgánicos
- Compuestos de cloro
- Sistema digestivo y fenómenos fisiológicos orales
- Compuestos de sodio
- Odontología
- Fenómenos fisiológicos dentales
- Cloruros
- Ácido clorhídrico
- Bupivacaína
- Oclusión dental
- Cloruro de sodio
- tetra-4-amidinofenoxipropano
Otros números de identificación del estudio
Otros números de identificación del estudio
- UWM-TAP-TAPP-2025
- 19/2025/IX (Otro identificador: Ethics Committee Approval Number - Warmian-Masurian Chamber of Physicians in Olsztyn)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Individual participant data (IPD) will not be shared because this is a single-center, investigator-initiated academic study involving a limited number of participants. The collected data include sensitive personal and clinical information that cannot be fully anonymized without compromising data integrity. Only aggregated, de-identified results will be published in peer-reviewed journals and conference presentations.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .